8-K: Coeptis Therapeutics Granted Nasdaq Extension to Regain Listing Compliance

Coeptis Therapeutics has been granted an extension until January 15, 2025, by the Nasdaq Hearings Panel to regain compliance with the minimum bid price requirement for continued listing.

Summary

• Coeptis Therapeutics received a notice from Nasdaq on January 29, 2024, stating they were not in compliance with the minimum bid price requirement of $1.00 per share.
• The company was initially given until July 29, 2024, to regain compliance.
• Coeptis did not meet the minimum stockholders equity requirement of $5,000,000 for an additional extension.
• The company appealed the decision and presented a plan to address the issue on September 12th, including a potential reverse stock split.
• On September 17, 2024, Nasdaq granted Coeptis an extension until January 15, 2025, to regain compliance with the minimum bid price requirement.
• The company's stock will continue to trade on the Nasdaq Capital Market during this extension period.
• If Coeptis does not regain compliance by January 15, 2025, they may face delisting from Nasdaq.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the company's non-compliance with Nasdaq listing requirements and the potential for delisting. While an extension was granted, the underlying issue of a low stock price remains a concern.

Positives

• Coeptis has been granted an extension to maintain its listing on the Nasdaq Capital Market.
• The company has additional time to regain compliance with the minimum bid price requirement.
• The company's stock will continue to trade on Nasdaq during the extension period.

Negatives

• Coeptis was initially found to be non-compliant with Nasdaq's minimum bid price requirement.
• The company failed to regain compliance within the initial 180-day period.
• Coeptis did not meet the minimum stockholders equity requirement for an additional extension.
• The company faces potential delisting if it does not regain compliance by January 15, 2025.

Risks

• Coeptis may not be able to regain compliance with the minimum bid price requirement by January 15, 2025.
• Failure to regain compliance could result in the delisting of the company's stock from the Nasdaq Capital Market.
• The company's stock price may be volatile due to the uncertainty surrounding its listing status.
• The company's plan to address the minimum bid price requirement includes a potential reverse stock split, which could negatively impact shareholders.

Future Outlook

Coeptis must regain compliance with the Nasdaq minimum bid price requirement by January 15, 2025, or face potential delisting. The company intends to monitor its stock price and implement measures to regain compliance.

Management Comments

• Dave Mehalick, President and Chief Executive Officer of Coeptis, stated they are pleased with the decision from Nasdaq to grant the extension.
• Management stated they look forward to regaining and maintaining compliance with Nasdaq's continued listing requirements.
• Management stated they will continue to focus on their goal of improving patient outcomes.

Industry Context

This announcement is relevant to the biopharmaceutical industry as it highlights the challenges faced by companies in maintaining their stock listing on major exchanges. It also underscores the importance of meeting financial and regulatory requirements to ensure continued access to capital markets.

Comparison to Industry Standards

• Many small-cap biopharmaceutical companies face challenges in maintaining a minimum share price, especially during periods of market volatility or when clinical trial results are delayed or negative.
• Companies like Coeptis, which are in the development stage, often rely on capital markets for funding, making compliance with listing requirements crucial.
• Other companies in the sector that have faced similar challenges include [hypothetical company A] and [hypothetical company B], which have also had to implement reverse stock splits or seek extensions to maintain their Nasdaq listings.
• The minimum bid price requirement is a common hurdle for companies with volatile stock prices, and the extension granted to Coeptis is not unusual in the industry.

Stakeholder Impact

• Shareholders face the risk of potential delisting and further stock price decline.
• Employees may experience uncertainty regarding the company's future.
• Customers and partners may be concerned about the company's long-term viability.

Next Steps

• Coeptis will continue to monitor the closing bid price of its Common Stock.
• The company will seek to regain compliance with all applicable Nasdaq requirements within the allotted compliance period.
• Coeptis may implement a reverse stock split to address the minimum bid price requirement.

Key Dates

Keywords

Nasdaq, listing compliance, minimum bid price, delisting, reverse stock split, extension, biopharmaceutical, cell therapy